October 2025
1. ROESSLER N, Miszczyk M, Berger W, Englinger B, et al
   Nectin-4 in bladder cancer: biology and predictive biomarker potential.
   Curr Opin Urol. 2025 Oct 23. doi: 10.1097/MOU.0000000000001354.
   

   >> Share

   
   
2. PRADERE B, Schuit M, Guerrero-Ramos F, Shariat SF, et al
   Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.
   Curr Opin Urol. 2025 Oct 8. doi: 10.1097/MOU.0000000000001350.
   

   >> Share

   
   September 2025
3. WONG CH, Leung DK, Gontero P, Teoh JY, et al
   Gene-mediated therapy for BCG-unresponsive nonmuscle-invasive bladder cancer: mechanisms, clinical evidence, and practical implementation.
   Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001345.
   

   >> Share

   
   
4. GABRIEL PE, Horowitz A, Sfakianos JP, Xylinas E, et al
   Targeted therapies for Bacillus Calmette-Guerin unresponsive nonmuscle-invasive bladder cancer: a narrative review.
   Curr Opin Urol. 2025 Sep 19. doi: 10.1097/MOU.0000000000001343.
   

   >> Share

   
   
5. OUALLA K, Alem M, Teoh J
   Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer.
   Curr Opin Urol. 2025 Sep 15. doi: 10.1097/MOU.0000000000001334.
   

   >> Share

   
   
6. KITAMURA H, Nishiyama N
   Oncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and future directions.
   Curr Opin Urol. 2025 Sep 8. doi: 10.1097/MOU.0000000000001331.
   

   >> Share

   
   
7. MASTROLEO F, Marvaso G, Jereczek-Fossa BA
   Artificial intelligence in muscle-invasive bladder cancer: opportunities, challenges, and clinical impact.
   Curr Opin Urol. 2025;35:543-548.
   

   >> Share

   
   August 2025
8. BRACCO FM, Wong CHM, Teoh JYC
   Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development.
   Curr Opin Urol. 2025 Aug 25. doi: 10.1097/MOU.0000000000001330.
   

   >> Share

   
   
9. GUERRERO-RAMOS F, Gomez-Canizo C, Hernandez-Arroyo M, Subiela JD, et al
   Hyperthermic intravesical chemotherapy for Bacillus Calmette-Guerin-unresponsive nonmuscle-invasive bladder cancer.
   Curr Opin Urol. 2025 Aug 14. doi: 10.1097/MOU.0000000000001329.
   

   >> Share

   
   July 2025
10. ULERI A, Katzendorn O, Khene ZE, Xylinas E, et al
    Novel intravesical delivery systems for nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2025 Jul 17. doi: 10.1097/MOU.0000000000001326.
    

    >> Share

    
    
11. ZAURITO P, Scilipoti P, Montorsi F, Briganti A, et al
    Intravesical chemotherapy combination treatments for BCG-unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2025 Jul 15. doi: 10.1097/MOU.0000000000001324.
    

    >> Share

    
    
12. ARTILES MEDINA A, Subiela JD, Pichler R, Guerrero-Ramos F, et al
    Traditional and next-generation bacillus Calmette-Guerin based treatment strategies for bacillus Calmette-Guerin unresponsive non-muscle-invasive bladder cancer in the era of emerging therapies.
    Curr Opin Urol. 2025 Jul 14. doi: 10.1097/MOU.0000000000001319.
    

    >> Share

    
    
13. BABAEVSKAYA D, Morozov A, Fridman E, Tsoy L, et al
    En bloc resection of large bladder tumor: is it feasible and reasonable?
    Curr Opin Urol. 2025;35:385-389.
    

    >> Share

    
    June 2025
14. SULEJA A, Laukhtina E, Cormio A, Miszczyk M, et al
    Adjuvant radiotherapy following radical cystectomy in patients with muscle-invasive bladder cancer: a narrative review.
    Curr Opin Urol. 2025 Jun 23. doi: 10.1097/MOU.0000000000001310.
    

    >> Share

    
    May 2025
15. RUDER S, Martinez J, Palmer J, Arham AB, et al
    Antibody-drug conjugates in urothelial carcinoma: current status and future.
    Curr Opin Urol. 2025;35:292-300.
    

    >> Share

    
    January 2025
16. CADENAR A, Mancon S, Shariat SF, D'Andrea D, et al
    Is there a role for neoadjuvant therapies followed by radical cystectomy in oligometastatic bladder cancer?
    Curr Opin Urol. 2025 Jan 17. doi: 10.1097/MOU.0000000000001261.
    

    >> Share

    
    November 2024
17. PASTORINO GL, Mercinelli C, Necchi A
    The role of MRI in muscle-invasive bladder cancer: an update from the last two years.
    Curr Opin Urol. 2024 Nov 12. doi: 10.1097/MOU.0000000000001249.
    

    >> Share

    
    
18. BEN-DAVID R, Mehrazin R, Attalla K, Wiklund P, et al
    Tumor-informed circulating tumor DNA in urothelial carcinoma: a promising novel biomarker.
    Curr Opin Urol. 2024;34:464-470.
    

    >> Share

    
    October 2024
19. GROBET-JEANDIN E, Roupret M, Seisen T
    Novel intravesical therapies and delivery systems for the management of bladder cancer.
    Curr Opin Urol. 2024 Oct 8. doi: 10.1097/MOU.0000000000001232.
    

    >> Share

    
    September 2024
20. PFAIL J, Lichtbroun B, Golombos DM, Jang TL, et al
    The role of radical cystectomy and lymphadenectomy in the management of bladder cancer with clinically positive lymph node involvement.
    Curr Opin Urol. 2024 Sep 26. doi: 10.1097/MOU.0000000000001230.
    

    >> Share

    
    
21. LAUKHTINA E, Moschini M, Teoh JY, Shariat SF, et al
    Perioperative platform for muscle-invasive bladder cancer trials: designs and endpoints.
    Curr Opin Urol. 2024 Sep 12. doi: 10.1097/MOU.0000000000001228.
    

    >> Share

    
    
22. LAUKHTINA E, Moschini M, Teoh JY, Shariat SF, et al
    Bladder sparing options for muscle-invasive bladder cancer.
    Curr Opin Urol. 2024 Sep 3. doi: 10.1097/MOU.0000000000001220.
    

    >> Share

    
    
23. KURNOT JA, Kaye DR
    Reducing financial toxicity in bladder cancer care.
    Curr Opin Urol. 2024 Sep 2. doi: 10.1097/MOU.0000000000001218.
    

    >> Share

    
    August 2024
24. XIA L, Daneshmand S
    Does radical cystectomy still have a role in BCG-unresponsive nonmuscle invasive bladder cancer?
    Curr Opin Urol. 2024 Aug 20. doi: 10.1097/MOU.0000000000001213.
    

    >> Share

    
    July 2024
25. FAZEKAS T, Miszczyk M, Matsukawa A, Nyirady P, et al
    Defining oligometastatic state in uro-oncological cancers.
    Curr Opin Urol. 2024;34:261-265.
    

    >> Share

    
    May 2024
26. OBIREDDY SR, Lai WF
    Advances in preclinical approaches for intravesical therapy of bladder cancer.
    Curr Opin Urol. 2024 May 17. doi: 10.1097/MOU.0000000000001186.
    

    >> Share

    
    April 2024
27. GRAUSENBURGER R, Herek P, Shariat SF, Englinger B, et al
    Recent contributions of single-cell and spatial profiling to the understanding of bladder cancer.
    Curr Opin Urol. 2024 Apr 23. doi: 10.1097/MOU.0000000000001183.
    

    >> Share

    
    
28. ERTL I, Shariat SF, Berger W, Englinger B, et al
    Preclinical models for bladder cancer therapy research.
    Curr Opin Urol. 2024 Apr 17. doi: 10.1097/MOU.0000000000001182.
    

    >> Share

    
    
29. ENGLINGER B
    Molecular research in bladder cancer.
    Curr Opin Urol. 2024 Apr 12. doi: 10.1097/MOU.0000000000001181.
    

    >> Share

    
    
30. NOSSING C, Herek P, Shariat SF, Berger W, et al
    Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
    Curr Opin Urol. 2024 Apr 11. doi: 10.1097/MOU.0000000000001177.
    

    >> Share

    
    
31. ABUFARAJ M, Al Karmi J, Bdeir A
    Is there a role for metastasis-directed therapy in bladder cancer?
    Curr Opin Urol. 2024 Apr 5. doi: 10.1097/MOU.0000000000001174.
    

    >> Share

    
    March 2024
32. CALLERIS G, von Deimling M, Kesch C, Soria F, et al
    Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology.
    Curr Opin Urol. 2024 Mar 1. doi: 10.1097/MOU.0000000000001170.
    

    >> Share

    
    January 2024
33. GELIKMAN DG, Rais-Bahrami S, Pinto PA, Turkbey B, et al
    AI-powered radiomics: revolutionizing detection of urologic malignancies.
    Curr Opin Urol. 2024;34:1-7.
    

    >> Share

    
    
34. IKEDA A, Nosato H
    Overview of current applications and trends in artificial intelligence for cystoscopy and transurethral resection of bladder tumours.
    Curr Opin Urol. 2024;34:27-31.
    

    >> Share

    
    November 2023
35. CANCEL-TASSIN G, Koutros S
    Use of genomic markers to improve epidemiologic and clinical research in urology.
    Curr Opin Urol. 2023;33:414-420.
    

    >> Share

    
    July 2023
36. DE ANGELIS M, Basile G, Scornajenghi CM, Asero V, et al
    Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jul 3. doi: 10.1097/MOU.0000000000001113.
    

    >> Share

    
    
37. YANAGISAWA T, Kawada T, von Deimling M, Laukhtina E, et al
    Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023.
    Curr Opin Urol. 2023;33:258-268.
    

    >> Share

    
    June 2023
38. MELLEMA JJ, van Rhijn BWG, van der Heijden MS
    Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jun 3. doi: 10.1097/MOU.0000000000001107.
    

    >> Share

    
    May 2023
39. KRAJEWSKI W, Laszkiewicz J, Nowak L, Szydelko T, et al
    Current methods facilitating diagnosis of upper tract urothelial carcinoma: a comprehensive literature review.
    Curr Opin Urol. 2023;33:230-238.
    

    >> Share

    
    April 2023
40. KATIMS AB, Bochner BH
    Extended pelvic lymph node dissection in muscle invasive bladder cancer.
    Curr Opin Urol. 2023 Apr 7. doi: 10.1097/MOU.0000000000001096.
    

    >> Share

    
    March 2023
41. MUIN D, Laukhtina E, Hacker M, Shariat SF, et al
    PET in bladder cancer imaging.
    Curr Opin Urol. 2023 Mar 7. doi: 10.1097/MOU.0000000000001090.
    

    >> Share

    
    
42. BERNDL F, Frerichmann J, Berndl T
    Prevention and management of urinary tract infections after cystectomy.
    Curr Opin Urol. 2023 Mar 3. doi: 10.1097/MOU.0000000000001085.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share